Stock Ratings / Health Care / SABS / financials

EIKN (47) AGEN (26) CABA (42) IPSC (28) ⌘ Pro Terminal →

SAB Biotherapeutics Inc. (SABS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.23 +0.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.23

SAB Biotherapeutics Inc. (SABS) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $293.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.23 (-0.02%)🧬 Dilution Drag (+2.20% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SABS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY SABS SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 7.07 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)

FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 60.2 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.20% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.98-15.1% Next Q

Q2 (-2Q)

Grade D$2.53+12.3% Next Q

Q3 (-1Q)

Grade D$2.84+13.7% Next Q

Current

Grade D$3.23-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SABS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SABS currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.26) and Max Pain ($3.39) forces dealer call-delta covering toward $5.41.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.20% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SABS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SABS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SABS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.2M

FY24

Rev $1.3M

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-1.2%	$13.3M	-$45.7M	-27.4%
FY 2024	$1.3M	52%	-80%	-$34.1M	-$34.6M	-45%
FY 2023	$2.2M	52%	-80%	-$42.2M	-$25.1M	-27.4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SABS)

✓Walkthrough of SABS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SABS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.64%▼ DESCENDING CHANNEL

2026-10-30O $3.20H $3.37L $3.11C $3.23VOL 741.1K

RES: $3.82SUP: $2.36SMA50: $3.26SMA200: $3.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SABS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SABS Butterfly Map → + Track SABS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

15.8%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SABS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SABS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SABS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SABS)

Health Care Rank #480 of 1016 ⚔️ EIKN vs SABS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SABS vs. EIKN, AGEN, CABA, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SAB Biotherapeutics Inc. (SABS) ranks #480 by composite RQD confidence (45/100, grade D) and #521 by equity capitalization ($293.9M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SABS at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SABS ACTIVE SAB Biotherapeutics Inc.	D	45/100	22.1x	—	-27.4%	+0.94%	$293.9M	Benchmark Subject
EIKN Eikon Therapeutics Inc.	D	47/100	—	—	—	-3.43%	$289.8M	/eikn-vs-sabs →
AGEN Agenus Inc.	E	26/100	—	96.0%	-35.0%	-0.56%	$320.2M	/agen-vs-sabs →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-sabs →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-sabs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001833214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SAB Biotherapeutics Inc. (SABS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $1.3M , and -100.0% cumulative change since FY2023) , GAAP net income of $13.3M, operating cash flow of -$44.8M, and free cash flow of -$45.7M (-32.0% YoY). On the balance sheet, SABS closed FY2025 with $172.8M in total assets against $0 in total debt (Altman Z-Score: 7.07, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$13.3M	-$44.8M	-$45.7M	$172.8M	—
FY2024 (FY)	2024-12-31	$1.3M	-$34.1M	-$34.3M	-$34.6M	$44.2M	—
FY2023 (FY)	2023-12-31	$2.2M	-$42.2M	-$25.1M	-$25.1M	—	—

3. SABS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SABS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SAB Biotherapeutics Inc. (NASDAQ: SABS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $3.23 (+0.94% 1D, market cap $293.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 4/20. Across 1016 tracked Health Care issuers, SABS ranks #480 in composite RQD confidence.

How does SABS compare to EIKN and AGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SABS carries a Roarable D (45/100 RQD), trailing P/E of 22.1x, gross margin of —, and ROIC of -27.4%. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $289.8M) and AGEN (Agenus Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $320.2M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SABS?

Per SABS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833214), SAB Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), $13.3M in net income, and -$45.7M in free cash flow against $172.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SABS trading relative to its 50-day, 200-day, and 52-week technical levels?

SABS last traded at $3.23 (+0.94% on volume of 458,282 shares), positioning the stock -0.92% below its 50-day simple moving average ($3.26) and -12.23% below its 200-day simple moving average ($3.68). Across its 52-week range of $2.44 to $5.15, SABS sits at the 29.2% percentile with a 14-day RSI of 60.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.83 to $3.63).

SABS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is SAB Biotherapeutics Inc. (SABS)?

In FY 2025 (10-K), SABS converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SABS RQD Cockpit SABS 12M Forecast SABS Earnings & Move SABS Dividends & DRIP SABS Insiders & 13F SABS Whale Options SABS Profit Sankey SABS News & Why